Presentation is loading. Please wait.

Presentation is loading. Please wait.

Pharmacological Management of Parkinson’s Disease

Similar presentations

Presentation on theme: "Pharmacological Management of Parkinson’s Disease"— Presentation transcript:

1 Pharmacological Management of Parkinson’s Disease
Dr EGS Spokes Consultant Neurologist Leeds General Infirmary

2 Background Very challenging - bespoke - not ‘off the peg’
Side effects pose major problems Before anticholinergics/amantadine/stereotactic surgery Since L-dopa L-dopa + peripheral DDCI Selegiline ( MAOB-I ) Bromocriptine Other Dopamine Agonists Apomorphine Entacapone ( COMT-I ) Before life expectancy c. 12 years - now improved

3 Levodopa Complications L-dopa Dopamine Reuptake
MAOB L-dopa DDC Dopamine Reuptake COMT Best treatment No response ? PD Complications c. 10% p.a. Related to duration/dosage Dose related motor fluctuations - wearing off ± dystonia - peak dose dyskinesia Random fluctuations Psychiatric disorder ? L-dopa accelerates cell death

4 Management of L-dopa Treatment Failures On/Off Chart

5 Management of L-dopa Treatment Failures
Dose related Wearing off ± dystonia fractionate dose / dispersible prolong effect with selegiline / entacopone add dopamine agonist Peak dose dyskinesia fractionate dose / reduce if possible amantadine Random as above + ? protein restriction apomorphine - penject / infusion

6 Dopamine Agonist Monotherapy
Ergot derivatives - Bromocriptine / Pergolide / Cabergoline Non-ergots Ropinirole / Pramipexole All associated with a lower incidence of motor fluctuations + dyskinesia c.5% Advantage less clear in >70’s Use if life expectancy ≥ 5 years ? Neuroprotective - Ropinirole PET study / Pramipexole SPECT study

7 Psychiatric Complications
Hallucinations - Delusions - Hypersexuality - Confusion Reduce / withdraw drugs in order : Anticholinergics Amantadine Selegiline ( ? try Zelapar if worse ) Entacapone Agonist L-dopa ? atypical neuroleptic - olanzapine / quetiapine / clozapine ? anticholinesterase

8 Non – Motor Problems Myalgia Depression Somnolence Dementia Autonomic
anticholinergic TCA / SSRI ? nocturnal sleep disturbed fractionate doses ? modafanil anticholinesterase postural hypotension constipation bladder disturbance sweating / flushing

Download ppt "Pharmacological Management of Parkinson’s Disease"

Similar presentations

Ads by Google